A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
NCT01712061
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
226
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetic Nephropathy
Interventions
DRUG:
PF-04634817
DRUG:
Placebo
Sponsor
Pfizer